Market Access
During his 40 years at Royal Philips, Bert van Meurs has seen the medical devices business grow in line with the evolving needs of healthcare providers with whom the company partners in customer and patient focused innovation.
Executives leading the commercialization of cell and gene therapies are informing how the industry approaches everything from manufacturing strategy to physician education.
Issues that had been concerns in Trump’s first term are realities now, but industry has also seen some successes. Trump’s personalistic style of governance means that larger firms may be at an advantage because of their greater flexibility to cut deals on individual products.
The pharmaceutical industry has been pushing back on a deeply unpopular rebate on products deemed to be “free combination” medicines in Germany.
Amid a decline in global clinical research share, the EU, UK and Switzerland have launched initiatives for fast-track reviews of clinical trial applications and set ambitious targets to shorten trial setup times.
The culmination of the MedTech Innovator APAC awards program 2025 comes later this month when the top prizes are handed out at the grand final in Singapore. But all cohort companies benefit from the competition’s mentoring process, says awards organizer Fredrik Nyberg.
Chinese medtechs are expanding rapidly worldwide, but gaining market access within China itself – poised to become the world’s largest medtech market – is proving to be a very different challenge.
A new report highlighting 62 key drug launches expected in 2026 includes five products that are predicted to hit a golden trifecta of being a first launch, having practice-changing potential and the promise of being a blockbuster.
The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.
C-suite executives from Stryker, Intuitive Surgical and Fresenius passed a mainly upbeat verdict on the Indian medtech market and industry. Their thoughts are encapsulated in part two of In Vivo’s APACMed 2025 conference review.
APACMed’s Asia-Pacific medtech forum moved outside Singapore for the first time in its 11-year history, to India, a country of big medtech ambitions and top five global market aspirations by 2035. This first In Vivo conference report describes India’s medtech infrastructure efforts.
June Raine was a “hard act to follow” at MHRA, but new chief executive Lawrence Tallon is looking to the future in setting out a vision for the UK regulator.
For months, US Health and Human Services Secretary Robert F. Kennedy Jr. had talked about banning direct-to-consumer television ads for prescription drugs. And now, he is making good on his promise – but in a roundabout way.
The gap between investor returns and patient returns is precisely that which the SALY/SADY framework is designed to fill.
Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.
Understand who’s influencing access decisions and how pharma can engage strategically across the continent.
John Arena, president of Global Pharma Services at Cencora, talks to In Vivo about how companies can strategize market entry for oncology products.
Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.